Last reviewed · How we verify
NCT03936023
Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims
trial testing Saxagliptin in Diabetes in 182,126 participants. Completed in 18 February 2021.
18 February 2021
Quick facts
| Lead sponsor | Brigham and Women's Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 182,126 |
| Start date | 22 September 2017 |
| Primary completion | 18 February 2021 |
| Estimated completion | 18 February 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Saxagliptin — full drug profile →
- Sulfonylurea — full drug profile →
Conditions studied
- Diabetes — all drugs for Diabetes →
Sponsor
Brigham and Women's Hospital
Who can join
40 and older, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
Franklin JM, Patorno E, Desai RJ, Glynn RJ, et al · · 2021 · cited 235× · PMID 33327727 · DOI 10.1161/circulationaha.120.051718
Verify or expand the search:
- PubMed search for NCT03936023
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Saxagliptin
Trials testing the same drug.
- NCT06099067 — Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) · completed
- NCT03199053 — Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) · Phase 3 · completed
- NCT02917031 — Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure · Phase 4 · completed
- NCT02681094 — A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administ · Phase 3 · completed
- NCT02471404 — Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes · Phase 4 · completed
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Brigham and Women's Hospital trials
Trials by the same sponsor.
- NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
- NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
- NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
- NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
- NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03936023 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03936023.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing